Recently considerable efforts have been devoted to the chemical modification and total synthesis1~4) of the representatives of the vancomycin group of antibiotics5) with a glycopeptide structure^and possessing antibacterial activity. This is clearly because that for the treatment of the continually threatening multi and methycillin-resistant Staphylococcus aureus (MRSA)infections, emerged in the past few decades, the only presently known effective medicines7'8) are the antibiotics vancomycin and/or theicoplanin. Furthermore, the appearance and increasingly spreading of the vancomycin-resistant Enterococci (VRE) also promoted related research.
The first reports on the structure and antibiotic activity of the glycopeptide-type antibiotic eremomycin (1) were published9 '10) in about ten years ago, and then later chemical modifications11M3) at the N-and C-terminal portions of the heptapeptide aglycone of 1 were also carried out.
The present paper deals with some novel chemical modifications of the eremomycin antibiotic (1) .
Eremomycin (1) readily reacted at the N-terminal pp.314 -319 secondary amino group with 2-chloroethylisocyanate (2) to furnish the 7V-(2-chloroethylureido) derivative 3, whichunder the conditions of isolation-transformed into the cyclic 2-oxazoline compound 4 in an intramolecular Sn2 reaction (Scheme 1). The oxazoline structure of 4 was justified by mass spectrometric measurements (Table 1) , as well as by NMRspectral data. Thus, the 500/125 MHz(ref: ext TMS)D2O/300K2D HETCOR spectrum unequivocally proved the presence of an extra NCH2(4.00/44.02 ppm) and an OCH2 (4.97/72.88ppm) unit as compared to the spectrum of the parent eremomycin (1) . Also characteristic is a nearly lppm shift (4^5ppm) of XI proton, demonstrating that the modification has occurred at the Nterminus. Based on the deuteration rate of the 5-NHproton, the dimerization constant of 4 is higher than that of eremomycin (1) , and perhaps this explains the biological activity of this compound.
The reaction of 1 with 2,3,4,6-tetra-O-acetyl-Dglucopyranosylisocyanate (5) afforded 7V- (2' ,3 ' ,4' ,6 ' -tetra-0-acetyl-a,/J-glucopyranosyl)thioureidoeremomycin (6).
Zemplen O-deacetylation14) of 6 and subsequent column chromatography allowed to isolate iV-(j3-and a-D-glucopyranosyl)thioureidoeremomycin (7 and 8) in pure form.
The a-anomer quantity was insufficient for NMR.For the attached glucose unit in the /3-anomer 7 the Gl anomeric signal was found at 5.89/86.3 ppm coordinates in the HETCORspectrum. The X1 proton is further shifted up field, and was found at the 6.35/62.1 ppm cross-peak coordinate. This compoundis a dimer, too. A most recent field of the research for fighting against MRSAand VRE is the synthesis of the covalent dimers of the glycopeptide antibiotics. American scientists15) 16) coupled two vancomyein molecules into a covalent "headto-head" dimer through the C-terminals, and English chemists17) preferred the preparation of a "head-to-tail" dimer of the antibiotic by means of the covalent dimerization involving the C-and TV-terminals. With these in mind we planned the synthesis of the covalent "tail-totail" dimers of the eremomycin antibiotic linked through the TV-terminal of the molecule (Scheme 1).
Considering the number of the primary and secondary amino groups of eremomycin (1), the intermolecular and intramolecular coupling with the bis-isocyanate derivative 9 could lead to the formation of various dimers. eremomycin derivatives 4-10 was performed on silanized silica gel columns with two-step gradient elution using 0.01 Maqueous acetic acid and 50%methanol. In the case of 10 this purification protocol was extended with subsequent elutions employing 40%methanol containing 0.04 macetic acid and 50%methanol containing 0.05 m acetic acid. The homogenity of the compound was represented by HPLC (Table 1 ).
The position of the introduced ureido and thioureido groups was determined after Edmandegradation and acid hydrolysis. Edman degradation showed that in all derivatives the 7V-methylamino group is substituted: TLC demonstrated the absence of 5-isopropyl-l-methyl-3-phenyl-2-thiohydantoin by comparison with an authentic sample of this latter, which was obtained in a parallel experiment by the Edmandegradation of eremomycin. 1 8)
We have shown19) previosly that hydrolysis of eremomycin in 0.2N HC1at 100°C for 10minutes leads to the splitting of the glycosidic bond between two sugars in the disacharide moiety, and gives rise to eremosamine. TLC comparison of the hydrolysis products of 4, 6-8 with an authentic sample of eremosamine revealed that eremosamine is not substituted in these compounds. The hydrolysis products of compound 10 contained aminosugars different from eremosamine. TLC and HPLC comparison of the hydrolysis products of 10, formed under more drastic conditions (37% HC1, 3hours., i.e. when the aglycone of eremomycin was obtained in a parallel hydrolysis of eremomycin), whith an authentic sample of the aglycone of eremomycin demonsrated the absence of this latter.
The structure of the covalent eremomycindimer 10 was proved by means of mass spectrometric investigations. By applying either the electrospray (ES-MS) or the MALDITOFtechnique, the molecular mass of 10 was found to be m/z=3681
( Table 1) . The m/z=S60 fragment ion in the MALDI-TOF spectrum corresponds to the structural unit ll split off from 10. A further proof for this structure is that the split disaccharide portion must be appeared at m/z=306. The observed molecular mass m/z=368l corresponds to a dimeric structure (10) in which two eremomycin molecules are coupled through the A^-terminus of the aglycone and the amino group of the disaccharide moiety. In addition, the two C-terminal carboxylic functions link two sodium ions, and the whole molecule is associated with one molecule of water. Consequently, protonation of this molecular complex under the electrospray or MALDI-TOF conditions leads to the formation of the peak m/z=3681. The covalent dimeric structure of 10 was also proved by NMRdiffusion experiments.20) Comparison of the spectrum of 10 with that oferemomycin (1) (DMSO, 330K) showed a difference of 0.ll on a log10 diffusion rate scale. This immediately translates to a mass ratio slightly bigger than two. In the 2D HETCORspectrum 8 aromatic CH protons are detected at 7.ll/129.6 ppm, and 4-4 CH groups at 7.54/121.23 and 7.36/119.58 ppm. In addition, 2XCH2 is observed at 3.84/40.88 ppm. These observations are in a good correspondence with the proposed structure 10 for the dimer.
The antibacterial activity of the synthesized ureidoeremomycinderivatives was tested on six Staphylococcus Fig. 1 . Structure of the mass fragment ll of the covalent dimer of eremomycin (10).
aureus strains, using oxacillin, methycillin, vancomycin and eremomycin as the reference materials ( Determined by the agar dilution method after an overnight incubation at 37°C Liquid medium: Nutrient Broth (104 CFU/ml) methycillin-sensitive and moderately methycillin-resistant, respectively, while all of the other strains are methycillinresistant (MRSA). The antibacterial activity of the samples was investigated at the concentrations 100 and 0.39 /ig/ml.
The biological tests revealed that the only compound which possessed higher activity than oxacillin and methycillin against the MRSAstrains was the modified antibiotic 4. At the same time, even this compound was still less effective than vancomycin and eremomycin. It is interesting to note that the /3-D-glucopyranosyl-thioureidoeremomycin derivative (7) was two times more efficient than the corresponding a-glucoside 8. The covalent eremomycin dimer 10, coupled from both sides, possesses a rather rigid structure, which unfavourably influences binding of this modified antibiotic to the 7V-acyl-D-Ala-DAla unit of the peptidoglycan moiety of the bacterial cellwall.
Eremomycin (1) 7V-Oxazoline of Eremomycin (4) To a solution of 165mg (O.lmmol) of eremomycin sulfate (1) in DMSO (3ml) was added 0.0085ml (0.1 mmol)of 2-chloroethylisocyanate and the reaction mixture was stirred for 2hours at room temperature. Then 50ml of acetone was added, the formed precipitate was filtered off, washed with acetone and dried in vacuum to afford 166 mg of the crude product 4. Purification was carried out by means of column chromatography employing a 2X30 cm column, and 400ml of0.01 Macetic acid (pH 4) at a rate of 0.3ml/minute. The fractions containing the pure title compoundwere pooled, and this solution was concentrated and frezee-dried to obtain 102mg (62%) of 4 as a white powder. Rf=0.35 (A^; Rf=0.09 (A2).
N-(2 ' ,3 ' ,4 ' ,6 ' -Tetra-O-acetyl-D-glucopyranosyl)thioureide of Eremomycin (6) A stirred solution of 50mg (0.03 mmol) of eremomycin sulfate (1) and 35 mg (0.09 mmol) of 2,3,4,6-tetra-<9-acetyl-D-glucopyranosylisothiocyanate in 1 ml of DMSOwas heated at 40~50°C for 2hours. After cooling to room temperature the reaction product wasprecipitated by the addition of acetone (30 ml). The precipitate was filtered off, washed with acetone, and dried in vacuum at room temperature to yield 58 mgof the crude 6. It was dissolved in 1 ml of water, loaded to a 1X30cmcolumn, and column chromatography was performed by step gradient elution from 0.01 Macetic acid in water to 50% methanol in 0.01 M acetic acid. The appropriate fractions (50% MeOH) were combined, concentrated to a small volume (-0.5 ml) and 30 ml of acetone was added. The precipitate produced was filtered off, washed with acetone, and dried in vacuumat room temperature to isolate 50mg (86%) of pure 6, Rf=0.55 (Aj); Rf=0.43 (A2).
-(/j-D-Glucopyranosytyhioureide of Eremomycin (7) and JV-( q-D-Glucopyranosyl)thioureide of Eremomycin (8) A stirred solution of 50mg (0.26mmol) of compound 6 in a 1 : 1 mixture of dry MeOH-DMF (2ml) was treated with 0.1m sodium methoxide in MeOH(pH=8) and stirring was continued for 3 days at room temperature. The reaction mixture was then diluted with acetone (30 ml), the precipitate formed was filtered off, washed with acetone, and dried in vacuumat roomtemperature to obtain 30mg of a mixture of two products (ratio is-3 : 1) as shown by TLCand^-NMRanalyses. This mixture was submitted to column chromatography as described above for compound 4, to furnish 20 mg,(45%) of the pure /?-anomer 7, Rf=0.02 (A^, (B). The a-anomer 8 was isolated from the mixture by repeated column chromatogrpahy to obtain 4mg (8%) of the product of 80-90% purity (TLC), Rf=0.02 (A^, Rf=0.5 (B). than that of the parent 1, and also -15% of a slowermoving product. The precipitated mixture was filtered off, washed with cold, dry MeOH, and then dissolved in 1.5 ml of 0.01 macetic acid. Purification was carried out on a 2X40cmcolumn by means of step gradient elution from 0.01M acetic acid (pH 4) to 50% MeOHin 0.05m acetic acid (pH 3) to obtain three fractions. The first fraction (from 0.01 Macetic acid) gave 80mg of the starting eremomycin (1) .
The second fraction (from 20% MeOHto 30% MeOHin 0.03M acetic acid) afforded a~2 : 1 mixture (TLC) of the faster-and slower-moving products.
The third fraction (from 40% MeOHin 0.04m acetic acid to 50% MeOHin 0.05m acetic acid) gave the desired faster-moving title dimeric compound 10 (6 mg). The methanol filtrate containing some of the product 10 was evaporated to dryness, and the residue was washed with acetone (2X l0ml). It was then dissolved in 0.5ml of water, and the product was precipitated with 20ml of acetone. 
